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Does Reverse Causality Underlie the Temporal Relationship 
Between Depression and Crohn’s Disease?
Lawrence S. Gaines, PhD,*,† James C. Slaughter, DPH,‡ David A. Schwartz, MD,* Dawn B. Beaulieu, MD,* 
Sara N. Horst, MD, MPH,* Robin L. Dalal, MD,* Elizabeth A. Scoville, MD,* Robert S. Sandler, MD,§ and 
Michael D. Kappelman, MD¶
Background: Studies suggest that there is a temporal relationship between depression and Crohn’s disease (CD) activity. However, these studies 
assumed a unidirectional relationship and did not examine the possibility of reverse causality and the risk of a spurious association due to the 
overlap of symptoms underlying the depression–CD relationship. We evaluated the existence of reverse causality reflected in a possible bidirec-
tional relationship between patient-reported CD activity and an affective–cognitive dimension of depression.
Methods: We studied 3307 adult volunteers with a self-reported diagnosis of CD who completed a baseline survey that included demographics, 
CD activity, and an affective–cognitive index of depression. Crohn’s disease status and the affective–cognitive index of depression were also meas-
ured 6 and 12 months after the baseline evaluation. We used structural equation models to evaluate whether the effect of depression on future CD 
activity is stronger than the effect of CD activity on future depression. We calculated the likelihood that each of these hypotheses is supported by 
the data and calculated the likelihood ratio to provide a relative measure of which hypothesis best accounts for the data.
Results: The results of the informative hypothesis testing showed the most support for the hypothesis stating that an affective–cognitive dimen-
sion of depression is a stronger predictor of patient-reported CD activity than the converse.
Conclusions: The hypothesis that an affective–cognitive dimension of depression predicts patient-reported exacerbation of CD is 218 times 
more likely to account for the data than the converse.
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INTRODUCTION
The rates of  depression among Crohn’s disease (CD) 
patients appear to be higher than in the general popula-
tion.1 Depression is an important comorbid condition for 
patients with CD, in part because it adversely affects quality 
of  life,2 reduces adherence to disease management,3 and pos-
sibly contributes to intestinal inflammation.4 This suggests 
that the recognition and treatment of  comorbid depression 
may positively influence the clinical course of  CD. However, 
more data are needed to fully evaluate whether depression is 
a consequence of  suffering from a chronic debilitating bowel 
disease, whether depression influences the course of  CD, 
or both.
Although there is evidence from clinic- and Internet-based 
longitudinal studies that depression is associated with worsening 
of CD,5, 6 these studies are limited because they were designed to 
examine the relationship between depression and CD unidirec-
tionally. However, it is also possible that worsening of CD may 
lead to depression, in addition to or instead of the effect of de-
pression on CD, that is, reverse causality. This is a challenging 
area of research because both CD and depressive symptoms gen-
erally have long induction periods, making it difficult to estab-
lish the precise period “at risk.” Yet, there are clear implications 
for both pathophysiology and treatment. Indeed, if depression 
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is a stronger predictor of CD activity than the converse, then this 
would further support the need to screen and treat for depression 
early in the clinical course of CD. In addition, most prospective 
studies of depressive state and CD activity do not provide a ra-
tionale for how exposure is conceptualized and operationalized 
and thus frequently use measures of depression with somatic 
symptoms, such as poor sleep or appetite, that could overlap with 
symptoms of CD and thus lead to a spurious relationship between 
depression and CD. Additionally, when the diagnostic category 
of depression is the desired measure of exposure, there is a greater 
chance of overlooking the specific depressive symptoms that may 
be responsible for the temporal relationship between a depressive 
state and the clinical course of CD. A recent study of possible bi-
directional relationships between anxiety and depression and in-
flammatory bowel disease measured depression with the Hospital 
Anxiety and Depression’s Depression subscale, which focuses on 
anhedonia, but it did not find evidence of bidirectionality be-
tween anhedonia qua depression and CD activity inferred from 
evidence of prescription of steroid medication, physicians’ global 
assessment of flares, escalation of medical therapy, or hospitaliza-
tion secondary to objectively confirmed IBD activity or intestinal 
resection.7 Another recent study, although not examining depres-
sion, reported a bidirectional relationship between self-reported 
stress, often an antecedent to depression, and patient-reported 
IBD symptoms, but no relationship between perceived stress and 
change in intestinal inflammation.8 The current study proposes to 
evaluate whether reverse causality underlies the relationship be-
tween patient-reported CD activity and depression in a previously 
published Internet-based study.6 Ascertainment of depression 
was restricted to 1 dimension of depression—affective–cognitive 
symptoms—because we wanted to eliminate the possibility of a 
spurious relationship resulting from the overlap between somatic 
symptoms of depression and CD. We used data from a sample 
of subjects in the Crohn’s and Colitis Foundation’s IBD Partners 
Internet cohort study. Analyses were conducted on data covering 
a 12-month period, providing an extended period to capture 
change in affective–cognitive symptoms of depression and CD. 
The objective of this study was to test whether a published finding 
of a temporal relationship between an affective–cognitive dimen-
sion of depression and patient-reported CD activity6 may have 
been the result of reverse causality. We hypothesized that there is 
a temporal relationship between an affective–cognitive dimension 
of depression and subsequent patient-reported CD activity be-
cause of the earlier finding.6 More specifically, the aim was to test 
the hypothesis that the influence of an affective–cognitive dimen-
sion of depression on patient-reported CD activity is stronger 
than the effect of CD activity on subsequent depression.
METHODS
Study Sample
IBD Partners, formerly known as CCFA Partners, is a 
longitudinal Internet-based cohort study sponsored by the 
Crohn’s and Colitis Foundation that has been described in 
detail in previous publications.9 In brief, participants had 
been invited to participate in the cohort through the Crohn’s 
and Colitis Foundation email roster, social media, and at ed-
ucational and fundraising events. Inclusion criteria included 
age >18 years, a self- reported diagnosis of IBD (Crohn’s di-
sease, ulcerative colitis, or indeterminate colitis), access to the 
Internet, and the ability to complete informed consent and 
surveys in English. There were no exclusion criteria. After en-
rollment, participants completed surveys at baseline and at 
6-month intervals to capture health behaviors, treatments, and
patient-reported outcomes. For this study, we analyzed data on
all participants with CD in the IBD Partners cohort who had
completed a baseline and 2 or more follow-up surveys.
Measures
Depression was measured using the National Institutes 
of Health’s Patient-Reported Outcomes Measurement 
Information Systems (PROMIS) 4-item form on Depression.10 
The PROMIS Depression questionnaire used in this study did 
not include items assessing somatic symptoms that overlap 
with symptoms of CD such as poor sleep, fatigue, and lack 
of appetite. The short form was composed of 4 Likert-type 
5-point items measuring the frequency of negative mood (I
felt depressed) and cognition, including negative beliefs about
the self  (I felt worthless, I felt helpless) and decreased life en-
gagement/negativity toward the future (I felt hopeless), during
the previous 7  days. All responses were summed to form a
raw score ranging from 4 to 20, which was then converted to
a standardized score (t-score). For all PROMIS measures, the
t-score for the standardized population is 50 with an SD equal
to 10. Thus, a t-score change from 55 to 65 represents a change
from 0.5 SDs to 1.5 SDs above the standardized population
mean. Disease activity was assessed by the short CD Activity
Index (SCDAI),11 a patient-reported measure. Disease activity
was modeled as both a continuous SCDAI t-score and a binary
outcome, with active disease being defined as a SCDAI t-score
>150. The SCDAI was developed to provide a shortened and
simplified CD Activity Index (CDAI) using patient self-report.
Covariates
The following variables were included in the regression 
models as potential confounders of the association between de-
pression and CD activity: age, sex, race, baseline SCDAI, di-
sease duration, use of biologic medication, body mass index, 
current smoking, level of educational attainment, and sleep 
quality.
Statistical Analysis
We summarized continuous variables by the median 
and 25th and 75th percentiles, and we summarized categorical 
variables using percentages. We used Spearman’s correlation to 
estimate the bivariate associations between depression and di-
sease activity at each time point.
We conducted structural equation modeling using the 
lavaan package with R. We fit a 3-wave cross-lagged model (Fig. 
1) with autoregression control paths and cross-lagged paths be-
tween time periods. The measures of depression and disease 
activity were log-transformed, centered, and scaled to have var-
iance of 1 so that all coefficient estimates correspond to a 1-SD 
increase on the log scale in depression or disease activity.
To phrase the research hypotheses in statistical notation, 
we represent the standardized regression estimates between de-
pression (d) at wave i and the CD activity index (c) at wave j by 
β dicj. The composite hypothesis that the effect of depression on 
future CD activity is always stronger than the effect of CD ac-
tivity on future depression is given by:
HA: β d2c3 > β c2d3 and β d1c3 > β c1d3 and β d1c2 > β c1d2, 
whereas the hypothesis that the effect of CD activity on 
future depression is always stronger than the effect of depres-
sion on future CD activity is given by: 
HB: β d2c3 < β c2d3 and β d1c3 < β c1d3 and β d1c2 < β c1d2.
We calculated the likelihood that each of these hypotheses 
is supported by the data and calculated the likelihood ratio to 
provide a relative measure of which was more likely.
RESULTS
We analyzed data from a total of 3307 CD volunteers 
who continued to participate to at least the second follow-up 
assessment. Baseline demographics and clinical characteristics 
are shown in Table 1. At baseline, the median age was 43 years. 
The median age at IBD diagnosis was 25 years, and the median 
period from initial diagnosis was 11 years. The sample was pre-
dominantly white females who were well educated, were taking 
immunosuppression therapy, and did not smoke. Pairwise 
correlations among depression and disease activity measures 
are shown in Table 2. We observed large correlations among 
depression measures at each of the 3 time points (r = 0.63 to 
0.67) and among the disease activity measures at 3 time points 
(r = 0.55 to 0.61). There were medium correlations between de-
pression and disease activity (r = 0.32 to 0.42), with somewhat 
higher correlations when measurements were obtained contem-
poraneously. All correlations were statistically significant due 
to the large sample size (all P < 0.001).
We estimated that the path from depression to disease 
activity was, on average, stronger than the path from di-
sease activity in a joint structural model. Table 3 shows the 
standardized parameter estimates with corresponding 95% 
confidence intervals from the proposed research model (Fig. 1). 
The strongest paths were between depression at T2 and depres-
sion at T1 (β, 0.64; 95% confidence interval [CI], 0.62 to 0.67) 
and depression at T3 and depression at T2 (β, 0.64; 95% CI, 
0.61 to 0.67). We also observed strong paths between disease 
activity at T2 and disease activity at T1 (β, 0.55; 95% CI, 0.52 to 
0.58) and depression at T3 and depression at T2 (β, 0.57; 95% 
CI, 0.54 to 0.60). For relationships between depression and di-
sease activity, all paths 1 time period apart had estimated confi-
dence intervals that did not contain 0. However, for association 
2 time periods apart, there was no evidence that T1 depression 
was associated with T3 disease activity (β, 0.03; 95% CI, –0.01 
to 0.06) and no evidence that T1 disease activity was associated 
with T3 depression (β, 0.02; 95% CI, –0.01 to 0.05) when ac-
counting for associations 1 time period apart. Disease activity 
at time 1 was associated with depression at time 2 (β,  0.05; 
95% CI, 0.03 to 0.08), and depression at time 1 was associated 
with disease activity at time 2 (β, 0.10; 95% CI, 0.07 to 0.13). 
Disease activity at time 2 was associated with depression at time 
3 (β, 0.08; 95% CI, 0.05 to 0.11), and depression at time 2 was 
associated with disease activity at time 3 (β, 0.08; 95% CI, 0.05 
to 0.12). That is, the estimated paths from depression to disease 
activity were larger than the paths from disease activity to de-
pression, with overlap of the confidence intervals. Confidence 
intervals for paths measured 2 time periods apart (depression 
at T3 with disease activity at T1 and disease activity at T3 with 
depression at T1) each contained the null value of 0, indicating 
a lack of evidence of a significant path. Finally, we formally 
compared the hypothesis that the effect of depression on future 
CD activity is always stronger than the effect of CD activity 
TABLE 1. Patient Demographics at Baseline (n = 3307)
a b c
Age at baseline, y 30 43 56
Age at IBD diagnosis, y 19 25 36







Height, in 63 66 69





Less than high school 1




Any immunosupression drug, %
 No 34
 Yes 66
a, b, and c represent the lower quartile a, the median b, and the upper quartile c for 
continuous variables. 
on future depression (Ha) vs the hypothesis that the effect of 
CD activity on future depression is always stronger than the 
effect of depression (Hb). We found that Ha was 218 times more 
likely than Hb, meaning that an affective–cognitive dimension 
of depression is a much stronger predictor of patient-reported 
disease activity over time than the converse.
DISCUSSION
Most of the earlier epidemiological studies of CD and 
comorbid depression5 suggest that there is a temporal relation-
ship between depression and CD activity. However, the results 
of earlier studies may be biased because of unexamined reverse 
causality, where CD might exert an influence on depression, 
in addition to or instead of the effect of depression on CD. 
As the assumption of unidirectional causality may seem un-
tenable in studying the association of depressive symptoms 
and exacerbation of CD,12, 13 we conducted a study that simul-
taneously analyzed the predictive role of depression on CD 
activity while also examining the role of CD activity on subse-
quent depression. In effect, our study attempted to answer the 
chicken-or-egg causality question in regard to the relationship 
of patient-reported CD activity and an affective–cognitive di-
mension of depression.
Our results support the hypothesis that affective–cog-
nitive aspects of depression brought about increased patient-
reported CD activity. We used a structural equation model 
TABLE 2. Correlations Among Depression and Disease Activity Measures at 3 Time Points
Variable Depression 1 SCDAI 1 Depression 2 SCDAI 2 Depression 3 SCDAI 3
Depression 1 1.00
SCDAI 1 0.42 1.00
Depression 2 0.66 0.32 1.00
SCDAI 2 0.34 0.60 0.41 1.00
Depression 3 0.63 0.32 0.67 0.36 1.00
SCDAI 3 0.32 0.55 0.33 0.01 0.41 1.00
SCDAI is the short form of the Crohns Disease Activity Index; Depression is the abbreviated short form of the PROMIS Depression scale.
TABLE 3. Parameter Estimates With 95% Confidence Intervals for the 3 Time Points Model
lhs rhs est se z P Lower CI Upper CI
Depression 2 Depression 1 0.644 0.014 45.0 <0.001 0.6162 0.672
Depression 2 SCDAI 1 0.053 0.014 3.7 0.002 0.0251 0.081
Depression 3 Depression 2 0.639 0.014 45.8 <0.001 0.6114 0.666
Depression 3 SCDAI 2 0.079 0.016 4.9 <0.001 0.0475 0.111
Depression 3 SCDAI 1 0.026 0.015 1.7 0.09 –0.0043 0.056
SCDAI 2 Depression 1 0.103 0.015 6.7 <0.001 0.0729 0.133
SCDAI 2 SCDAI 1 0.554 0.015 36.2 <0.001 0.5237 0.584
SCDAI 3 Depression 2 0.084 0.019 4.5 <0.001 0.0474 0.121
SCDAI 3 SCDAI 2 0.570 0.015 38.0 <0.001 0.5407 0.599
SCDAI 3 Depression 1 0.029 0.018 1.6 0.11 –0.0064 0.063
SCDAI is the short form of the Crohn’ Disease Activity Scale; Depression is the abbreviated short form of the PROMIS Depression Scale.
FIGURE 1. Estimated cross-lagged structural equation model. The proposed 3-wave reciprocal causation, cross-lagged model between depression 
and disease activity with numerical estimates of the standardized, adjusted associations between variables.
framework to examine inequality-constrained hypotheses that 
depression is a stronger predictor of CD than the converse. The 
results indicate that 1 model, that a selected dimension of de-
pression predicts exacerbation of CD, is 218 times more likely 
to account for the data than the converse.
These results are specific to a particular aspect of de-
pression and may not be found in other studies using measures 
with depression-related somatic symptoms such as appetite, 
fatigue, and sleep. The finding of a unidirectional relationship 
between an affective–cognitive dimension of depression and 
patient-reported CD activity provides new insights into the 
mechanisms underlying the temporal relationship. Heightened 
depression, especially the cognitive characteristics of negativity 
to the self  and the future examined in this study, may be a psy-
chological condition that influences CD morbidity through 
intervening lifestyle behaviors and related epigenetic and im-
munological processes. For example, the CD volunteers who 
reported the greatest negativity to the self  and the future and 
sadness at baseline were also more likely to be smokers who 
were overweight and less educated.6 Smoking and body weight 
are lifestyle characteristics that have relationships with epige-
netic and immune system processes underlying inflammatory 
bowel disease.14, 15 These potential mediators may be associated 
with other intermediary processes underlying dysfunction in 
the hypothalamic–pituitary–adrenal axis, which is theorized to 
account for the influence of depression on inflammatory bowel 
disease.16 A  potentially destructive feedback loop may exist 
whereby increased depression leads to poor self-care/high levels 
of illness behavior and then to poor immune system function, 
which in turn triggers flare-ups of CD.
The results of this study confirm the results of earlier pro-
spective studies indicating some deterioration of CD reflecting 
the impact of depressive state. However, this study was the first 
to test for possible bias from reverse causality in a published 
study of patient-reported CD activity and a single dimension 
of depressive symptoms instead of categorical depression per 
se. Our more detailed approach to understanding depression in 
examining the CD–depression relationship allows us to begin 
to consider what characteristics of depression affect patient-
reported CD or, more proximally, the underlying lifestyle 
mediators of the depression–CD relationship. In this study, the 
measure of exposure represents what we believe to be the de-
fining feature of depression, a loss of self-esteem and self-regard.
This study strongly supports the need for 
gastroenterologists to attend to their CD patients’ depression. 
Heightened depression, especially the cognitive characteristics 
of negativity to the self  and the future, may be a psychological 
condition that influences CD morbidity through physiological 
processes and indirectly via behavioral pathways.6 The health 
risk behaviors and psychobiological changes associated with 
depression-related lifestyles increase the risk for chronic med-
ical disorders.17 Now with greater confidence in the temporal 
relationship between an easily measurable aspect of depression 
and subsequent patient-reported CD exacerbation, the next 
step is to study what proximate factors such as lifestyle variables 
mediate the relationship between these 2 comorbid conditions. 
Maximizing the clinical usefulness of an established temporal 
relationship between depression and CD will require identifi-
cation of the proximate lifestyle processes intervening between 
depression as studied here and patient-reported CD activity 
level so that interventions can be focused and more effective at 
reducing flares.
The major strengths of this study are the large sample 
size and use of a patient-reported outcome measure that has 
been used with great usefulness by clinical researchers. The 
short CDAI is a valid, reliable, and responsive tool for the 
measurement of patient-reported CD activity. However, future 
observational studies of CD would benefit from the use of a 
multimethod approach to outcome measurement that would 
include objective measurement of inflammation in addition 
to the patient-reported level of disease activity, as has recently 
been used in the longitudinal study of stress and IBD.8 Also, 
the likelihood is high that patient-reported diagnosis of CD is 
valid, because prior CCFA Partners research found the match 
between patient and physician reports to be 97% for CD.18 
Appropriate methods for measuring exposure were achieved. 
In particular, the study provided a rationale for the selection of 
the exposure measure that represents what we believe to be the 
defining feature of depression and that allowed us to eliminate 
the possibility of a spurious relationship as a result of overlap 
in neurovegetative symptoms of depression and CD such as 
appetite and sleep. At this early stage in the history of under-
standing the depression–CD relationship, the use of a conven-
ience sample, although possibly restricting the generalizability 
of the finding of a unidirectional relationship, provides us with 
the opportunity to understand the depression–CD relation-
ship in a sample that may be rather typical as Internet-based 
studies become more common. Certainly the greater frequency 
of women using medical therapy in this study is consistent with 
data from epidemiological studies indicating that CD is more 
frequent in women.19 As to controlling bias due to attrition and 
confounding, we analyzed data from patients who volunteered 
at the initiation of the study and continued through to the third 
wave in this longitudinal study, which allowed us to avoid sample 
refreshment and attending interpretational difficulties. We sta-
tistically controlled for several known influences on CD and 
depression, such as the use of biologics. The longitudinal data 
were analyzed using estimated cross-lagged structural equation 
models for examining possible bidirectional relationships be-
tween CD and depression. Although the study presents several 
methodological strengths, one of its limitations is that we did 
not include other possible confounders that could influence the 
depression–CD relationship in more diverse samples of CD 
patients. For example, we did not collect data on patients’ his-
tory of depression, treatment for depression, or perceived stress 
associated with depression.
In conclusion, this study is an early answer to the ques-
tion of whether there is a temporal relationship between de-
pression and patient-reported CD activity. Our findings suggest 
that CD patients’ negative self-regard is clinically important 
to understanding change in patient reports of their CD ac-
tivity. Gastroenterologists should screen for affective–cognitive 
symptoms of depression in CD patients. Evaluation and treat-
ment of depression may improve the course of CD.
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